Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.
1. A bioactive polymeric liquid formulation comprising:
an absorbable, segmented, aliphatic polyurethane comprising polyoxyalkylene chains end-grafted with alkylene carbonate chains that include trimethylene carbonate sequences, the end-grafted polyoxyalkylene chains interlinked with aliphatic urethane segments that are derived from at least one diisocyanate selected from the group consisting of tetramethylene diisocyanate, hexamethylene diisocyanate, lysine-derived diisocyanate, and cyclohexane bis(methylene isocyanate), forming a polymer with an alternating chain structure of aliphatic urethane-alkylene carbonate-polyoxyalkylene-alkylene carbonate-aliphatic urethane;
wherein the polyoxyalkylene comprises poly(ethylene glycol) having a molecular weight of 400 Da;
at least one drug selected from the group consisting of doxycycline, mitomycin, clindamycin, miconazole, clotrimazole, ketoconazole, fluconazole, butoconazole, tioconazole, leflunomide, 5-fluorouracil, paclitaxel, carboplatin, mycophenolic acid, podophyllinic acid, podophyllotoxin; and
wherein the polyurethane is treated with 2-propanol to eliminate any unreacted isocyanate groups.